Kezar Life Sciences (KZR) Q3 2024 earnings summary

Executive summary

• Clinical-stage biotech focused on small molecule therapeutics for immune-mediated diseases, with lead candidate zetomipzomib targeting severe autoimmune conditions; focus shifted to autoimmune hepatitis (AIH) after terminating the PALIZADE Phase 2b lupus nephritis trial due to four fatal SAEs, with PORTOLA Phase 2a trial in AIH now completed enrollment and partially held by FDA.

• Topline data from the PORTOLA AIH trial expected in the first half of 2025, with 24 patients enrolled.

• KZR-261 oncology program enrollment stopped to reallocate resources; company remains pre-revenue from product sales.

• One-for-ten reverse stock split completed in October 2024 to maintain Nasdaq listing compliance; all share data retroactively adjusted.

Financial highlights

• Net loss of $20.3 million for Q3 2024 ($2.78/share), improved from $23.1 million ($3.18/share) in Q3 2023; net loss of $63.5 million for the nine months ended September 30, 2024, compared to $69.6 million for the same period in 2023.

• Research and development expenses decreased to $16.2 million in Q3 2024 from $23.7 million in Q3 2023, and to $49.7 million for the nine months ended September 30, 2024, from $63.1 million in 2023, mainly due to restructuring and reduced headcount.

• General and administrative expenses fell to $5.7 million in Q3 2024 from $8.8 million in Q3 2023, mainly due to lower legal and stock-based compensation costs.

• Cash, cash equivalents, and marketable securities totaled $148.4 million as of September 30, 2024, down from $201.4 million at year-end 2023.

• No product sales revenue; $7.0 million collaboration revenue recognized in 2023 from Everest Medicines upfront payment; no collaboration revenue in Q3 2024.

Outlook and guidance

• Cash runway expected to fund operations for at least 12 months from the financial statement issuance date.

• Topline data from the PORTOLA AIH trial expected in the first half of 2025.

• Company anticipates continued operating losses and will require additional capital for future development and commercialization.

• Focus shifting to zetomipzomib in autoimmune hepatitis following PALIZADE trial termination.